AP
PRTK

Appleton Partners’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

Appleton Partners’s Portfolio PRTK Stock Details PRTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-9,109
Closed -$229K – 262
2017
Q3 		$229K Hold
9,109
– – 0.04% 222
2017
Q2 		$220K Buy
+9,109
New +$201K 0.04% 227
2016
Q1 		– Sell
-10,109
Closed -$192K – 215
2015
Q4 		$192K Hold
10,109
– – 0.04% 207
2015
Q3 		$192K Buy
10,109
+66
+0.7% +$1.65K 0.04% 196
2015
Q2 		$259K Sell
10,043
-9,957
-50% -$283K 0.06% 162
2015
Q1 		$625K Sell
20,000
-20,000
-50% -$574K 0.14% 112
2014
Q4 		$1.54M Buy
+40,000
New +$955K 0.35% 70

Other funds holding PRTK

OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return
ECP
Empyrean Capital Partners Los Angeles, California $3.07B AUM 34.24% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return

Appleton Partners's PRTK Position: Q4 2017 in Review

Appleton Partners sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q4 2017, closing a stake of 9,109 shares — an estimated $229K sold.

Appleton Partners first reported a position in PRTK in Q4 2014 and held it in 7 quarters. The position peaked at $1.54M in Q4 2014. 116 funds tracked by Wall St. Rank hold PRTK as of Q4 2017.

  • Appleton Partners reported no remaining Paratek Pharmaceuticals, Inc. position as of Q4 2017 after selling out during the quarter.
  • Appleton Partners sold 9,109 Paratek Pharmaceuticals, Inc. shares in Q4 2017, an estimated $229K.
  • Appleton Partners first reported a position in Paratek Pharmaceuticals, Inc. in Q4 2014 and held it in 7 quarters.
  • Appleton Partners's Paratek Pharmaceuticals, Inc. position peaked at $1.54M in Q4 2014.
  • 116 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q4 2017.

Based on Appleton Partners's 13F filing for Q4 2017, filed 12 Jan 2018.